Clinical trials: Adenocarcinoma of the Pancreas
Pancreatic Adenocarcinoma
4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
The primary objective is to study the feasibility and efficacy of individually optimized CE 4D-CT for PDA in radiotherapy simulation.
- Trial name
- GCC 1210 (NCT01764659)
- Testing
- Contrast-enhanced 4D computed tomography
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Maryland, Baltimore
Pancreas Adenocarcinoma, Small-cell Lung Cancer
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard)…
- Conditions
- Pancreas Adenocarcinoma, Small-cell Lung Cancer, Glioblastoma, IDH-wildtype
- Trial name
- ROSALIND (NCT06160596)
- Testing
- Long term survival multimodal analysis
- Where
- France
- Volunteers
- 1,020 people
- Sponsor
- Cure 51
Pancreatic Cancer
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells.
- Trial name
- NCT00727441
- Testing
- GVAX pancreatic cancer vaccine, cyclophosphamide
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma
Diffusion MRI for Pancreatic Adenocarcinoma
The detection of small liver metastases represents a major challenge during the staging process of patients with pancreatic adenocarcinoma.
- Trial name
- PANDA (NCT02896946)
- Testing
- Diffusion-weighted nuclear magnetic resonance imaging
- Volunteers
- 118 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Cancer, Pancreas Adenocarcinoma
Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
We are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.
- Trial name
- NCT03544255
- Testing
- Biopsy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ying Lv
Pancreatic Cancer, Chemotherapy Effect
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of LM-302 combined with gemcitabine as a second-line treatment for CLDN 18.2-positive unresectable locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT07108504
- Testing
- Gemcitabine, LM-302
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer, PDAC
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- RASolute 304 (NCT07252232)
- Testing
- daraxonrasib
- Where
- 86 sites in United States, Canada and 8 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
Carcinoma, Pancreatic Ductal
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
The purpose of this study is to find out what effects, good and bad, the chemotherapy drugs gemcitabine (Gemzar) and paclitaxel (Taxol) have in combination with twice daily radiation treatment on locally advanced pancreatic…
- Trial name
- NCT00226746
- Testing
- Paclitaxel and gemcitabine
- Where
- United States
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Pancreas Adenocarcinoma, Pancreas Neoplasms
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
Endoscopic ultrasound (EUS) is a well-established tool for the diagnosis and staging of many gastrointestinal conditions, including but not limited to, malignant and pre-malignant neoplasms of the pancreas, esophagus, rectum, and…
- Conditions
- Pancreas Adenocarcinoma, Pancreas Neoplasms, Gastrointestinal Stromal Tumor, Lymphoma
- Trial name
- NCT01774162
- Testing
- Fine needle biopsy using ProCore needle for histology., Fine needle aspiration using conventional FNA for cytology
- Where
- 2 sites in Canada
- Volunteers
- 57 people
- Sponsor
- University of Alberta
Pancreatic Adenocarcinoma
A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
There are several types of early pre-cancerous lesions found in the pancreas which have the potential to develop into pancreatic cancer.
- Trial name
- PaC-MAn (NCT03840460)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma, Pancreatic Ductal
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal…
- Trial name
- CanStem111P (NCT02993731)
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 267 sites in United States, Australia and 18 more
- Volunteers
- 1,134 people
- Sponsor
- Sumitomo Pharma America, Inc.
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
Pancreatic Cancer
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than fluorouracil for pancreatic cancer.
- Trial name
- NCT00005871
- Testing
- fluorouracil, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Locally Advanced Pancreatic Adenocarcinoma
Surgery for Locally Unresectable Pancreatic Cancer
Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option.
- Trial name
- ROBIN (NCT07241663)
- Testing
- Questionnaire
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera di Padova
Cholangiocarcinoma, Pancreatic Cancer
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry
The objective of this protocol is to establish a multicenter registry to evaluate the impact of radiofrequency ablation in the management of patients with pancreatico-biliary disorders including malignancies.
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture
- Trial name
- RFA-Registry (NCT01439698)
- Testing
- Radio Frequency ablation Probe
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Pancreatic Neoplasms, Cancer of the Pancreas
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Background: In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%.
- Conditions
- Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer
- Trial name
- NCT01313416
- Testing
- CT-011, Gemcitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Augusta University
Pancreatic Cancer
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer.
- Trial name
- NCT00276744
- Testing
- cetuximab, capecitabine, docetaxel
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer of Pancreas
Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer
A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.
- Trial name
- PORTICO-SABR (NCT04128332)
- Testing
- Pre-operative stereotactic ablative body radiotherapy
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- CCTU- Cancer Theme
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.